Licensing status

Publication and contact information


Pancreatic cancer

ATG5 autophagy related 5 homolog (ATG5); ATG7; K-Ras (KRAS); p53

Mouse studies suggest inhibiting autophagy in KRAS-driven pancreatic ductal adenocarcinomas (PDACs) lacking p53 could accelerate tumor formation. In a mouse model of Kras-driven PDAC, Atg5- or Atg7-deficient mice that also lacked p53 had accelerated development of PDAC compared with mice with intact p53. In p53-deficient mice with PDAC, compared with those with intact p53, the autophagy inhibitor hydroxychloroquine accelerated PDAC formation and decreased survival. Next steps could include meta-analyses of data from clinical studies testing autophagy inhibitors.
Hydroxychloroquine, a generic inhibitor of autophagy, is in investigator-led Phase II trials for various cancers.

SciBX 7(2); doi:10.1038/scibx.2014.54
Published online Jan. 16, 2014

Unpatented; licensing status undisclosed

Rosenfeldt, M.T. et al. Nature; published online Dec. 4, 2013;
Contact: Kevin M. Ryan, The Beatson Institute for Cancer Research, Glasgow, U.K.